openPR Logo
Press release

Originator Small Molecule Drug Market- Key Players | Novartis AG, Roche, Glaxosmithkline Plc., Boehringer Ingelheim International GmbH, Genentech, Amgen, Inc., Gilead, and Bristol-Myers Squibb Company,

03-13-2019 09:23 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fact.MR

/ PR Agency: Fact.MR
Originator Small Molecule Drug Market- Key Players | Novartis

Small molecule drugs are the ones with low molecular weight, generally less than 900 daltons. 90% of the drugs in the market are small molecule drugs of which 50% are derived from pre-existed metabolites and 30% of genetic disorder. Since small molecule drugs have low molecular weight, they are easily absorbable and can pass through the cell membrane.

Due to low molecular weight, small molecule drugs can travel to the desired location easily and achieve desired therapeutic effect. Originator small molecule drugs are the ones that are new in the market and under patent. In some cases small molecule drugs are protected by multiple patents due to difference in the dosage or route of administration or strength. In 2005, on an average, each originator small molecule drug had 3.5 patents.

Originator small molecule drugs are used to treat various diseases that are termed as dreaded in the recent time, e.g., cancer, diabetes, epilepsy, etc. Though biologics have impregnable efficacy as compared to originator small molecule drugs, long-term usage of biologics causes tolerance to the particular drug.

The diverse usage of originator small molecule drugs range from chronic diseases such as cancer and diabetes to more humane ailments such as cold, fever and cough. Usage of small molecule drugs such as aspirin ranges from daily pains and aches to cancer treatment, Alzheimer’s disease, and cardiovascular health. Aspirin was an originator small molecule drug patented under Kaiser.

Request For Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1519

Originator Small Molecule Drug Market: Drivers and Restraints

The diverse usage of originator small molecule drugs in the recent times has put them in a good shape and are being studied for different usages, e.g. Vertex Pharmaceuticals’ Ivacaftor is the first originator small molecule drug for the treatment of protein malfunctioning caused by the genetic defect in cystic fibrosis patients. Diverse availability of dosage form for administration depending on the age of patient is a major factor driving the growth of the originator small molecule drugs market.

Originator small molecule drugs are easy produce, highly profitable and scalable when compared to biologics. On an average originator small molecule drug costs US$ 1/day to produce, whereas biologics roughly costs US$ 22/day to produce. In 2017, FDA has approved total 28 originator small molecule drugs (new molecular entities), which shows the extent of ongoing research on originator small molecule drugs. Whereas in the current scenario, biologics are in trend for treatment of dreaded diseases such as cancer and diabetes due to their higher efficacy, which is expected to restrain the growth of the originator small molecule market.

Request For Brochure @ https://www.factmr.com/connectus/sample?flag=B&rep_id=1519

Originator Small Molecule Drug Market: Overview

The originator small molecule drug market is expected to have significant growth as most of the pharmaceutical companies are investing highly on research and development of novel drug formulation for the treatment of complex diseases. Higher focus on manufacturing innovative drugs is expected to contribute significantly to the growth of the originator small molecule drug market.

By drug class, the originator small molecule drug market is expected to be dominated by anti-cancer drugs segment. By indication type, the oncology segment expected to dominate the originator small molecule drug market. Whereas, by distribution channel, the retail pharmacies segment is expected to dominate the originator small molecule drug market over the forecast period.

Originator Small Molecule Drug Market: Regional Outlook

The global originator small molecule drug market is expected to be dominated by North America due to favorable reimbursements. Europe is expected to be the second large market for originator small molecule drugs. Asia-Pacific is expected to be the emerging market for originator small molecule drug due to affordability and reimbursement scenarios. The Middle East and Africa is expected to have sluggish growth in the global originator small molecule drug market.

Originator Small Molecule Drug Market: Key Players

Examples of some of the key participants operating in the global originator small molecule drug market are Novartis AG, Roche, Glaxosmithkline Plc., Boehringer Ingelheim International GmbH, Genentech, Amgen, Inc., Gilead, and Bristol-Myers Squibb Company, among others.

Report Analysis @ https://www.factmr.com/report/1519/originator-small-molecule-drug-market

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Read Industrial News : http://insiderstribune.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Originator Small Molecule Drug Market- Key Players | Novartis AG, Roche, Glaxosmithkline Plc., Boehringer Ingelheim International GmbH, Genentech, Amgen, Inc., Gilead, and Bristol-Myers Squibb Company, here

News-ID: 1650778 • Views: 291

More Releases from Fact.MR

11-09-2020 | Health & Medicine
Fact.MR
PCR and Real-time PCR Molecular Diagnostics Market to Surpass US$ 6 Bn by 2030, …
As per data from the World Health Organization, millions of deaths can be attributed to diseases such as cancer and HIV each year. Further, the recent outbreak of the COVID-19 virus has also created massive demand for effective diagnostics processes. The PCR and real-time PCR molecular diagnostics market has been gaining traction in recent years on the back of investments by PCR diagnostic test manufacturers towards the incorporation of molecular
10-05-2020 | Health & Medicine
Fact.MR
Biobanking Market to Soar to US$ 3.5 Bn by 2027, Notes Fact.MR
Biobanks are a type of repository which is used in the storage of biological samples, including human and animal tissues, which primarily find use in research applications. Consequently, the process of biobanking has become a very important part of medical research and has played a major role in modern science fields such as personalized medications, and genomics. The global biobanking market is expected to grow at a healthy CAGR of ~
Mini LED Market to Expand 7.5X by 2030, Finds New Study by Fact.MR
In recent years, increasing popularity of OLED TVs in China and India has been significantly influencing growth of the mini LED market. With an increase in disposable income of a majority of the population in these countries, the inclination towards smart screens with higher lifespan and better performance is expected to open up numerous growth opportunities for the mini LED market. Moreover, aspiring and affluent households have increased their spending
Uncertainty Surrounding COVID-19 to Shave-off Growth in Electrical Steel Market …
The global electrical steel market has utilized the opportunities in the market over the last decade with sales of electrical steel pegged at US$ 20.4 Bn in 2019. However, sales are set to plummet during in the middle two quarters of 2020 owing to COVID-19. In addition, several automakers have shuttered their production units, causing incalculable loss to the electrical steel market in 2020. However, the demand of electrical steel

All 5 Releases


More Releases for Originator

Originator Small Molecule Drug Market Trends, Regulations And Competitive Landsc …
Small molecule drugs are the ones with low molecular weight, generally less than 900 daltons. 90% of the drugs in the market are small molecule drugs of which 50% are derived from pre-existed metabolites and 30% of genetic disorder. Since small molecule drugs have low molecular weight, they are easily absorbable and can pass through the cell membrane. Due to low molecular weight, small molecule drugs can travel to the
Lake Michigan Credit Union hires Tiffany Homuth to Mortgage Loan Originator for …
Lake Michigan Credit Union (LMCU) of Florida is pleased to announce the hiring of Tiffany Homuth as a mortgage loan originator for its Collier Boulevard branch in Naples, Florida. She reports directly to LMCU’s Vice President of Regional Mortgage Production, Jayne Malinowski, and will be serving the southwest Florida market. Homuth graduated from the University of Southern Indiana in 1997 with a Bachelor of Science degree in communications/public relations and a
Originator Small Molecule Drug Market Outlook Exhibits Sustained Growth during t …
Small molecule drugs are the ones with low molecular weight, generally less than 900 daltons. 90% of the drugs in the market are small molecule drugs of which 50% are derived from pre-existed metabolites and 30% of genetic disorder. Since small molecule drugs have low molecular weight, they are easily absorbable and can pass through the cell membrane. Due to low molecular weight, small molecule drugs can travel to the
Global DNA Vaccine Pipeline Analysis
he global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three
Global Cell Therapy Pipeline Analysis
“Global Cell Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Cell Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each